Vytrus Biotech H1 FY26 net profit climbs 73% to EUR 2.5 million

• Vytrus Biotech H1 2026 net sales rose 37% to EUR 6 million.
• EBITDA climbed 67% to EUR 3.48 million; EBITDA margin widened 10.3 percentage points to 57.9%.
• Net profit increased 73% to EUR 2.5 million; operating cash flow rose 91% to EUR 2.75 million.
• EU net sales grew 49% while U.S. net sales fell 14%; trailing 12-month net sales reached EUR 10 million.
• Launched Toleroxyl on July 1, the first product from its recombinant-protein platform, to broaden beyond plant stem cells.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vytrus Biotech SA published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.